Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subject 18 years or older
Diagnosis of B-cell lymphoma (CD20+) of
* follicular lymphoma (grades 1, 2, and 3) or
* marginal zone lymphoma (extranodal, nodal, and splenic)
Documented relapse or progression following prior anti-neoplastic treatment.
At least 1 measurable lymph node mass that is \>1.5 cm.
No active CNS lymphoma
Voluntary consent
You may not be if
Previous treatment with VELCADE
Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug.
Any treatment with nitrosoureas within 6 weeks before the first dose of study drug.
Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug.
Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug.
Radiation therapy within 3 weeks before the first dose of study drug.
Major surgery within 2 weeks before the first dose of study drug.
Peripheral neuropathy or neuropathic pain
History of allergic reaction attributable to compounds containing boron or mannitol
Known anaphylaxis or hypersensitivity to any component of rituximab
Diagnosed or treated for a selected malignancies other than NHL within 5 years.
Active systemic infection requiring treatment
Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study.
Male subjects who do not agree to use an acceptable method of contraception for the duration of the study
Any serious medical or psychiatric illness likely to interfere with participation in this clinical study
Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
Clareo Health | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
